The Novo and Merck-backed pruritus therapy developer has filed to raise up to $97.8m, having already secured almost $110m in VC funding.
Menlo Therapeutics, a US-based pruritus treatment developer that counts pharmaceutical firms Novo and Merck & Co as backers, has filed for a $97.8m initial public offering on the Nasdaq Global Market.
The company is working on a therapy called serlopitant, which could be the first to get approval in the US to combat pruritus, an itch that is associated with skin conditions like psoriasis, atopic dermatitis or prurigo nodularis.
The IPO proceeds will go to complete phase 2 clinical…
